XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.2
EARNINGS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Stock option awards850,489 1,345,914 866,612 1,111,271 
Restricted stock awards429,782 48,690 431,444 591,176 
Performance stock unit awards331,370 — 246,157 152,189 
Schedule of Basic and Diluted Earnings Per Share
The following table presents the Company’s basic earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Numerator:
Net income (1)$53,043 $114,403 $97,834 $153,611 
Denominator:
Weighted average number of common shares outstanding172,927 179,807 173,428 180,531 
Earnings per common share:
Earnings per common share, basic$0.31 $0.64 $0.56 $0.85 
(1) Net income for the three and six months ended June 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.
The following table presents the Company’s diluted earnings per share and shares outstanding (in thousands, except per share data):
Three Months Ended June 30,Six Months Ended June 30,
 2024202320242023
Numerator:
Net income (1)$53,043 $114,403 $97,834 $153,611 
Denominator:
Weighted average number of common shares outstanding172,927 179,807 173,428 180,531 
Effect of dilutive securities1,163 1,434 1,403 1,400 
Weighted average number of common shares outstanding, diluted174,090 181,241 174,831 181,931 
Earnings per common share:
Earnings per common share, diluted$0.30 $0.63 $0.56 $0.84 
(1) Net income for the three and six months ended June 30, 2023 includes $62.8 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes.